Many approaches to molecularly targeted therapies have been investigated in clinical trials, and now the targeted treatment of relapsed gliomas with the BRAFV600E mutation with the BRAF kinase inhibitor dabrafenib in combination with the MEK inhibitor trametinib has provided strong evidence of clinical benefit [30,178,179]. This evidence concerns the gene BRAF and central nervous system cancer.